澳大利亚和新西兰肾移植受者皮肤癌死亡率:1990-2019年基于关联健康数据的队列研究
肾移植受者皮肤癌死亡率为118.2/10万人年,标化死亡比(SMR)为一般人群的11.1倍,其中角质形成细胞癌(KC)为34.5倍,黑色素瘤为4.5倍;高紫外线辐射地区超额死亡率最高。
要点
- 肾移植受者皮肤癌死亡风险是一般人群的11.1倍,KC死亡风险高达34.5倍。
- 高紫外线辐射地区(如昆士兰州SMR 14.8)超额死亡率最高。
- 所有性别、年龄组和随访年代均观察到超额皮肤癌死亡。
核心结论
- 肾移植受者皮肤癌死亡风险显著高于一般人群,尤其KC,所有人口学特征和地区均存在超额死亡。
- 高紫外线辐射指数地区超额死亡率最高,需加强监测和快速治疗。
研究设计与样本
- 基于人群的队列研究,链接澳大利亚和新西兰透析与移植登记处与两国国家死亡登记数据,1990-2019年。
主要发现
- 共251例皮肤癌死亡,其中黑色素瘤82例,KC 169例。
- 皮肤癌绝对死亡率为118.2/10万人年(95%CI 104.1-134.2),黑色素瘤为38.6/10万人年(95%CI 31.1-48.0),KC为79.6/10万人年(95%CI 68.5-92.6)。
- 总体SMR为11.1,黑色素瘤SMR为4.5,KC SMR为34.5。
- 昆士兰州SMR 14.8(95%CI 11.7-18.8),西澳大利亚州SMR 13.1(95%CI 8.7-19.7),新西兰SMR 11.0(95%CI 8.3-14.6)。
临床怎么用
- 对肾移植受者应加强皮肤癌监测和快速治疗转诊。
- 在高紫外线辐射地区应特别强调皮肤癌预防和早期诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transplant recipients have an increased risk of skin cancer and related death compared with the general population. How demographics or geography impact on mortality is unclear. Understanding these will help identify groups at highest risk of skin cancer death. OBJECTIVES: To estimate skin cancer mortality rates among kidney transplant recipients in Australia and New Zealand and describe excess mortality by demographics and geography, relative to the general population, and change over time. METHODS: We linked kidney transplant recipients from the Australia and New Zealand Dialysis and Transplant Registry with National Death Registers in Australia and New Zealand from 1990 to 2019. We identified deaths from melanoma (International Classification of Diseases 10th Revision code C43), keratinocyte cancer (KC; C44) and carcinoma in situ (D04), and estimated absolute mortality per 100 000 person-years of follow-up (PY). We used indirect standardization to estimate standardized mortality ratios (SMRs) with 95% confidence intervals (CIs) for kidney transplant recipients compared with the general population by sex, age at death, decade of death, and New Zealand or Australian state. RESULTS: We included 21 503 individuals who received their first kidney transplant between 1990 and 2019. There were 251 deaths from skin cancer, 82 from melanoma and 169 from KC, over 212 317 PY of follow-up. The absolute skin cancer mortality rate was 118.2 per 100 000 PY (95% CI 104.1-134.2), 38.6 per 100 000 PY for melanoma (95% CI 31.1-48.0) and 79.6 per 100 000 PY for KC (95% CI 68.5-92.6). Skin cancer mortality was 11.1 times higher in kidney transplant recipients compared with the general population (SMR) overall, 4.5 times higher for melanoma and 34.5 times higher for KC. Excess skin cancer mortality relative to the general population was observed in both sexes, across all age groups, residential areas and decades of follow-up. Excess mortality was highest in regions with high ultraviolet radiation (UVR) indices - the Australian states of Queensland (SMR 14.8, 95% CI 11.7-18.8) and Western Australia (SMR 13.1, 95% CI 8.7-19.7), and in New Zealand (SMR 11.0, 95% CI 8.3-14.6). CONCLUSIONS: Kidney transplant recipients are at increased risk of skin cancer death, especially from KC, in all demographics and regions in Australia and New Zealand, especially those with high UVR indices. Enhanced surveillance and rapid treatment entry are warranted. People who have had an organ transplant have a higher risk of getting skin cancer and dying from it. This is partly due to the medications they have to take to prevent transplant rejection. However, we don’t know whether the risks of getting skin cancer and dying from it have changed over time. We also don’t know if people’s age, sex or where they live influences their risk of dying from skin cancer. We studied everyone who received a kidney transplant from 1990 to 2019 in Australia and New Zealand. We calculated how many transplant recipients died of skin cancer. We then compared the results to the general population. We did this to find out whether how often people died of skin cancer was different for transplant recipients. We found that people with kidney transplants were 11 times more likely to die of skin cancer. We then broke this down by type of skin cancer. Transplant recipients were four times more likely to die of melanoma. (Melanoma is the deadliest type of skin cancer in the general population.) They were also about 34 times more likely to die from non-melanoma skin cancer. Compared to the general population, women, young and middle-aged kidney transplant recipients, and people from areas with very high UV radiation from the sun died more often from skin cancer. Our findings highlight how important early diagnosis and treatment are for transplant recipients with skin cancer. Patients and doctors should be reminded how important it is to try and prevent skin cancer developing to begin with.
引用
- Forcey DS, Rosales BM, Wyld ML, et al. Skin cancer mortality in Australian and New Zealand kidney transplant recipients: a population-based cohort study using linked health data, 1990-2019. Br J Dermatol. 2026. PMID: 42243641. doi:10.1093/bjd/ljag232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。